Biotech · Public company · Palo Alto, CA, US
Kodiak Sciences Inc.
Ticker KOD · SEC CIK 0001468748
Track this companyFree. Adds Kodiak Sciences Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials124 recruiting or active
Pipeline programs22From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline22
- AfliberceptPhase 3 · Diabetic Macular EdemaClinicalTrials.gov · fetched Nov 12, 2026
- AfliberceptPhase 3 · Macular EdemaClinicalTrials.gov · fetched Nov 12, 2026
- AfliberceptPhase 3 · Wet Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- AfliberceptPhase 3 · Wet Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- Aflibercept (2.0 mg)Phase 3 · Diabetic Macular Edema (DME)ClinicalTrials.gov · fetched Nov 12, 2026
- KSI-101Phase 3 · Macular Edema Secondary to InflammationClinicalTrials.gov · fetched Nov 12, 2026
- KSI-301Phase 3 · Diabetic Macular EdemaClinicalTrials.gov · fetched Nov 12, 2026
- KSI-301Phase 3 · Macular EdemaClinicalTrials.gov · fetched Nov 12, 2026
- KSI-301Phase 3 · Non-proliferative Diabetic RetinopathyClinicalTrials.gov · fetched Nov 12, 2026
- KSI-301Phase 3 · Wet Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- KSI-301Phase 3 · Wet Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- Sham ComparatorPhase 3 · Macular Edema Secondary to InflammationClinicalTrials.gov · fetched Nov 12, 2026
- Sham injectionPhase 3 · Non-proliferative Diabetic RetinopathyClinicalTrials.gov · fetched Nov 12, 2026
- Sham injectionPhase 3 · Diabetic RetinopathyClinicalTrials.gov · fetched Nov 12, 2026
- Sham ProcedurePhase 3 · Macular EdemaClinicalTrials.gov · fetched Nov 12, 2026
- Sham ProcedurePhase 3 · Wet Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- Sham ProcedurePhase 3 · Wet Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- Sham ProcedurePhase 3 · Diabetic Macular EdemaClinicalTrials.gov · fetched Nov 12, 2026
- Tabirafusp tedromerPhase 3 · Diabetic Macular Edema (DME)ClinicalTrials.gov · fetched Nov 12, 2026
- Tabirafusp tedromerPhase 3 · Wet Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- TarcocimabPhase 3 · Diabetic RetinopathyClinicalTrials.gov · fetched Nov 12, 2026
- Tarcocimab tedromerPhase 3 · Wet Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials12
- A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTOPHASE3 · RECRUITING · started Aug 3, 2026ClinicalTrials.gov NCT07734844 · fetched Nov 12, 2026
- A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAKPHASE3 · RECRUITING · started Jul 30, 2025ClinicalTrials.gov NCT06990399 · fetched Nov 12, 2026
- A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLEPHASE3 · RECRUITING · started Jul 16, 2025ClinicalTrials.gov NCT06996080 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAKPHASE3 · ACTIVE_NOT_RECRUITING · started Aug 23, 2024ClinicalTrials.gov NCT06556368 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)PHASE3 · COMPLETED · started May 1, 2024ClinicalTrials.gov NCT06270836 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)PHASE3 · TERMINATED · started Sep 7, 2021ClinicalTrials.gov NCT05066230 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)PHASE3 · COMPLETED · started Jun 23, 2021ClinicalTrials.gov NCT04964089 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)PHASE3 · TERMINATED · started Sep 30, 2020ClinicalTrials.gov NCT04603937 · fetched Nov 12, 2026
- A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)PHASE3 · TERMINATED · started Sep 30, 2020ClinicalTrials.gov NCT04611152 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)PHASE3 · COMPLETED · started Sep 25, 2020ClinicalTrials.gov NCT04592419 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.PHASE2_PHASE3 · TERMINATED · started Oct 8, 2019ClinicalTrials.gov NCT04049266 · fetched Nov 12, 2026
- Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVOPHASE1 · TERMINATED · started Dec 26, 2018ClinicalTrials.gov NCT03790852 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Sep 28, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 4, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 31, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 31, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 27, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Dec 18, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Nov 13, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 13, 2025 · fetched Nov 12, 2026